Receptor

A receptor is a specialized protein capable of specifically recognizing and binding a molecule called a ligand (peptide, hormone, neurotransmitter, growth factor, drug) to trigger a cellular response. It is the biological anchor point allowing a signaling molecule — often tiny and abundant in blood — to unlock massive changes inside the cell. The ligand-receptor encounter is the first act of molecular pharmacology, without which no biological action is possible.

Receptors fall into four major families based on architecture and transduction mode. G-protein coupled receptors (GPCRs) are the most numerous (>800 members in humans) and most pharmacologically exploited: they receive major peptide ligands (GLP-1, GIP, glucagon, ghrelin, oxytocin, melanocortins, opioids). Receptor tyrosine kinases (RTKs) transmit growth factor signals (insulin, IGF-1, EGF, VEGF, FGF). Ion-channel receptors operate in milliseconds and are exploited by fast neurotransmitters (GABA, glycine, glutamate). Intracellular nuclear receptors (steroids, thyroid, vitamin D) directly regulate gene transcription.

Receptor specificity for its ligand rests on geometric and chemical complementarity between the binding site (a pocket within the protein) and the incoming molecule. This interaction is characterized by the dissociation constant Kd: the lower it is (nM, pM), the higher the affinity. EC50, the concentration producing 50% of maximal effect, measures functional potency. A good therapeutic peptide combines high affinity (Kd <1 nM) and strong intrinsic efficacy (maximal receptor activation). Semaglutide, for instance, has a Kd of 0.08 nM on the GLP-1 receptor, about 20 times stronger than native GLP-1.

Three sophistication levels exist in ligand-receptor interaction. A full agonist fully activates the receptor and reproduces the endogenous ligand response. A partial agonist activates the receptor but with lower maximal efficacy — as seen with the glucagon receptor in retatrutide, where partial agonism avoids hyperglycemia. An antagonist blocks the site without activating the receptor, serving either as an antidote (naloxone against opioids) or experimental tool to demonstrate effect specificity. Biased agonists preferentially direct signaling toward certain pathways (e.g., beta-arrestin vs G-protein) and represent a major pharmacological innovation frontier.

Understanding a peptide's receptor is essential for designing rigorous experimentation. Receptor tissue distribution (brain, pancreas, muscle, adipose tissue, gut) predicts target organs. Expression density details expected local potency. Desensitization after prolonged exposure (tachyphylaxis, receptor internalization) may limit chronic effects. Modern scientific publications map all these parameters via expression atlases (Human Protein Atlas, GTEx) and guide research protocol design.